Kodiak Sciences Inc. still has options for KSI-301, but they are narrower now that the Phase IIb/III DAZZLE study in wet age-related macular degeneration (AMD) failed to meet its primary endpoint of showing non-inferior visual acuity gains for patients dosed on extended regimens compared with Regeneron Pharmaceuticals, Inc.’s Eylea (aflibercept). Now the drug’s most likely path forward is in diabetic macular edema (DME) and retinal vein occlusion (RVO), as well as potentially monthly dosing for wet AMD based on an ongoing trial.
Kodiak’s KSI-301 Has Narrower Path Forward After Phase II/III Failure In Wet AMD
Monthly dosing remains a possibility in wet age-related macular degeneration, though diabetic macular edema and retinal vein occlusion look more promising.
More from Sensory
• By
The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.
• By
But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.
• By
The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.
• By
The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.
More from Therapy Areas
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.